The battle against Alzheimer's disease (AD) has been long and challenging. However, in recent years, novel Disease Modifying Therapies (DMTs) using monoclonal antibodies (mAbs) have been developed. While promising, these DMTs require careful monitoring of patients against adverse effects once the treatment begins. On brain MRI, these adverse effects present as Amyloid Related Imaging Abnormalities (AIRA) with vasogenic edema and/or sulcal effusion (ARIA-E) and/or microhemorrhages or superficial siderosis (ARIA-H). Standardized, appropriate protocols for dementia therapeutic imaging are important. The American Society for Neuroradiology (ASNR) has partnered with equipment manufacturers to present optimized AD therapeutic imaging protocols. Washington University School of Medicine shares their imaging protocols for 1.5T and 3T MRI systems.
Reference: Cogswell, Petrice M., et al. "Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice." American Journal of Neuroradiology 43.9 (2022): E19-E35. http://www.ajnr.org/content/43/9/E19.abstract
Tammie L.S. Benzinger, M.D., Ph.D.
Washington University School of Medicine in St. Louis
Mallinckrodt Institute of Radiology, Box 8131
Neuroimaging Laboratories Research Center (NIL-RC)
4525 Scott Ave., Room 2115
St. Louis, MO 63110